Homology Medicines Inc (NASDAQ:FIXX) shot up 5.7% on Tuesday . The company traded as high as $18.61 and last traded at $18.57, 272,083 shares changed hands during mid-day trading. An increase of 12% from the average session volume of 243,964 shares. The stock had previously closed at $17.57.
A number of brokerages have weighed in on FIXX. Robert W. Baird began coverage on shares of Homology Medicines in a report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target for the company. FIX began coverage on shares of Homology Medicines in a report on Thursday, October 31st. They issued a “market perform” rating for the company. Zacks Investment Research downgraded shares of Homology Medicines from a “hold” rating to a “sell” rating in a report on Friday, November 15th. Oppenheimer began coverage on shares of Homology Medicines in a report on Friday, November 1st. They issued a “market perform” rating for the company. Finally, ValuEngine downgraded shares of Homology Medicines from a “buy” rating to a “hold” rating in a report on Monday, November 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Homology Medicines presently has an average rating of “Hold” and an average target price of $31.40.
The company has a market capitalization of $800.11 million, a PE ratio of -9.29 and a beta of 0.14. The business’s 50 day simple moving average is $14.35 and its 200 day simple moving average is $17.44.
Hedge funds have recently bought and sold shares of the business. Aperio Group LLC purchased a new stake in Homology Medicines during the second quarter valued at about $34,000. Bank of Montreal Can acquired a new position in shares of Homology Medicines in the 2nd quarter valued at about $40,000. Cubist Systematic Strategies LLC acquired a new position in shares of Homology Medicines in the 2nd quarter valued at about $42,000. Marshall Wace LLP acquired a new position in shares of Homology Medicines in the 1st quarter valued at about $74,000. Finally, Royal Bank of Canada increased its holdings in shares of Homology Medicines by 300.0% in the 2nd quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after purchasing an additional 3,000 shares during the period. 73.71% of the stock is owned by institutional investors.
About Homology Medicines (NASDAQ:FIXX)
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Story: What is range trading?
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.